Efficacy of Rebamipide in the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Breaks: A Systematic Review and Meta-Analysis.

A major limitation of these drugs is gastrointestinal (GI) mucosal injury.

这些药物的一个主要局限性是胃肠道（GI）粘膜损伤。

Several gastroprotective agents have been recommended but are limited by their long-term effects.

已推荐多种胃黏膜保护剂，但其长期效果有限。

Rebamipide is a promising mucoprotective agent, but its efficacy is not established.

雷贝前列素是一种有前景的黏膜保护剂，但其疗效尚未确定。

We performed a meta-analysisassessing the efficacy of rebamipide in preventing NSAID-induced GI mucosal breaks as compared with placebo and the standard proton-pump inhibitors (PPIs).

我们进行了一项荟萃分析，评估雷贝前列素在预防非甾体抗炎药（NSAIDs）引起的胃肠道黏膜损伤方面的疗效，与安慰剂和标准质子泵抑制剂（PPIs）进行了比较。

Methods

Four electronic databases were searched from inception to October 2023 for randomized controlled trials that compared rebamipide with placebo or PPIs.

从数据库启动到2023年10月，我们对四个电子数据库进行了搜索，以寻找比较雷贝前列素与安慰剂或PPIs的随机对照试验。

Data were pooled to obtain the risk ratio (RR) with 95% confidence interval(CI).

数据被汇总以获得风险比（RR）及其95%置信区间（CI）。

Heterogeneity and publication bias were assessed with I2 statistic and funnel plot, respectively.

使用I2统计量和漏斗图分别评估了异质性和发表偏倚。

Results

A total of 472 studies were screened, with 13 studies included.

共筛选了472项研究，最终纳入了13项研究。

Pooled analyses showed that rebamipide significantly reduced the incidenceof NSAID-induced GI mucosal breaks as compared with placebo (RR 0.55, 95% CI 0.31-0.99, P ≤ 0.00001).

汇总分析显示，与安慰剂相比，雷贝前列素显著降低了非甾体抗炎药引起的胃肠道粘膜损伤的发生率（相对风险 RR 0.55，95% 置信区间 0.31-0.99，P ≤ 0.00001）。

Rebamipide is also comparable with the standard PPIs in preventing NSAID-induced mucosal breaks (RR 1.00, 95% CI 0.51-1.95, P = 1.00).

Rebamipide 在预防非甾体抗炎药（NSAIDs）引起的粘膜损伤方面与标准质子泵抑制剂（PPIs）相当（相对风险 RR 1.00，95% 置信区间 CI 0.51-1.95，P = 1.00）。

Regarding addition of rebamipide to PPIs, there are still insufficient data to support its effect on further improving prevention of GI mucosal breaks as compared with PPIs alone (RR 0.72, 95% CI 0.43-1.21; P = 0.11).

关于将 rebamipide 添加到 PPIs 中，目前尚无足够数据支持其在进一步改善预防胃肠道粘膜损伤方面与单独使用 PPIs 相比有显著效果（相对风险 RR 0.72，95% 置信区间 CI 0.43-1.21；P = 0.11）。

Discussion

Rebamipide is effective in preventing NSAID-induced GI mucosal breaks.

雷贝拉唑在预防非甾体抗炎药（NSAID）引起的胃肠道粘膜损伤方面是有效的。

Rebamipide may also be as good as the standard PPIs in preventing NSAID-induced GI mucosal breaks and, hence, may be an alternative, especially in those with contraindications to long-term PPI use.

雷贝拉唑在预防非甾体抗炎药（NSAID）引起的胃肠道粘膜损伤方面可能与标准质子泵抑制剂（PPIs）一样有效，因此，对于长期使用PPIs有禁忌症的患者来说，它可能是一个替代选择。